PrecisionLife

PrecisionLife and Ovation identify first genetic biomarkers to quantitatively predict GLP-1 efficacy response PrecisionLife and Ovation identify genetic biomarkers to predict GLP-1 response and expand their partnership to develop precision prescribing tools.

PrecisionLife & Ovation identify the first genetic biomarkers to quantitatively predict GLP-1 treatment response.

Results from 4,600 patients show how genetics can help predict efficacy and improve outcomes.

Read more:
precisionlife.com/first-geneti...

Why is precision urgently needed for GLP-1 coverage?
Demand is surging, costs remain high, and patient responses vary.

Predictive biomarkers can help payors prioritize coverage where GLP-1s deliver the most value, while protecting affordability and access.

#GLP1 #PrecisionMedicine #ValueBasedCare

Those lovely people @actionforme.bsky.social have shared the recording of the webinar covering presentation of @precisionlife.bsky.social LOCOME results.
#MECFS #longcovid

www.youtube.com/watch?v=ITZ3...

WEBINAR TODAY:
Our researchers are unpacking the new ME genetics study today - join the live webinar to hear the findings first-hand and get your questions answered.

📅 Today
🕑 2PM GMT
🔗 Register: us02web.zoom.us/webinar/regi...

#pwME #MECFS #longCOVID #MissingMillions

The most detailed genetic analysis of myalgic encephalomyelitis ever conducted Groundbreaking ME study identifies 250+ genes, links with long COVID, and uncovers new drug repurposing opportunities to advance targeted treatments

Helen Baxter, Patient Advocate and PPI Representative:
"These results greatly enhance our understanding of the biology of ME and present opportunities for drug repurposing which affords hope to the millions of people living with #ME and #longCOVID around the world." @precisionlife.bsky.social

Identification of Novel Reproducible Combinatorial Genetic Risk Factors for Myalgic Encephalomyelitis in the DecodeME Patient Cohort and Commonalities with Long COVID Background: Myalgic encephalomyelitis (also known as ME/CFS or simply ME) has severely impacted the lives of tens of millions of people globally, but the disease currently has no accurate diagnostic t...

LOCOME Project: Major #ME and #LongCOVID Genetics Findings Announced. Today we are excited to share landmark new findings from the LOCOME project.
www.medrxiv.org/content/10.6...
@precisionlife.bsky.social

Identification of Novel Reproducible Combinatorial Genetic Risk Factors for Myalgic Encephalomyelitis in the DecodeME Patient Cohort and Commonalities with Long COVID Background: Myalgic encephalomyelitis (also known as ME/CFS or simply ME) has severely impacted the lives of tens of millions of people globally, but the disease currently has no accurate diagnostic t...

Delighted how @precisionlife.bsky.social and @actionforme.bsky.social et al used consented @decodemestudy.bsky.social data to
-replicate #MEcfs genetic signal &
-show its shared/distinct genetics with Long Covid.
Next: replicate ME/CFS subtypes w/ targeted therapies
www.medrxiv.org/content/10.6...

(1/4) 🧬 @precisionlife.bsky.social has released exciting results from the LOCOME project

Using DecodeME and other datasets, LOCOME has identified a number of genetic signals and biological pathways that may be involved in ME.

New myalgic encephalomyelitis (ME, also known as ME/CFS) genetics study reveals 250+ core genes, shared mechanisms with long COVID, and dozens of drug repurposing opportunities. This would not have been possible without the thousands of people with ME who contributed their data.
Thank you.

PrecisionLife & Ovation partner to develop first precision medicine test to inform reimbursement of GLP-1 anti-obesity drugs PrecisionLife and Ovation partner to develop real-world GLP-1 drug-response biomarkers to support value-based reimbursement and improve patient outcomes.

We’ve partnered with Ovation.io to identify biomarkers that predict which patients will respond safely and effectively to GLP-1 therapies.

The goal: help payors and providers achieve the best, most cost-effective outcomes for patients using GLP-1.

➡️ www.precisionlife.com/glp1 for more.

In a new article in Healthcare Leader, our CEO Steve Gardner explains how by understanding the biological mechanisms behind chronic conditions we can now predict and prevent complex diseases, improve diagnosis, treatment and patient outcomes. Read it here: precisionlife.com/healthcarele...

Why would anyone take on what is arguably the most complex of the complex, chronic diseases?

That’s the question Cort Johnson, founder of leading patient advocacy site Health Rising, asks in his latest feature about our work in ME/CFS and Long COVID.

➡️ www.healthrising.org/blog/2025/10...

Yesterday at #TechBioUK - hosted by @bia-uk.bsky.social - our CEO Steve Gardner joined leaders from AstraZeneca, Healx and Recursion to explore the real-world impact of AI in drug development and healthcare – and what’s needed for it to reach its full potential.

What do you think?

Our 2025 Big Survey is now open! 🎉

For more information, our FAQs, and to take part, head to our web page: www.actionforme.org.uk/research-campaigns/our-research-work/big-survey/

Thank you for supporting our research💙

🤝in collaboration with
@durhamimh.bsky.social @kacheston.bsky.social

A new way of looking at endometriosis, with Rowan Gardner | Overlooked: women's health can't wait Even a basic definition of endometriosis tells us a lot about why we need to rethink how we’re dealing with this condition. Rowan Gardner is co-founder of...

Thank you to Golda Arthur for inviting me to be on the Overlooked Pod. A curation of conversations about women's health from patients, clinicians and scientists. Highlighting @precisionlife.bsky.social's work in #endometriosis and #womenshealth
check out the series
overlookedpod.com/episode/a-ne...

Our SVP of Bioinformatics, Sayoni Das, shared new insights at #WomenInBiotech: 75 novel genes linked to #endometriosis, confirmed across diverse populations. A step toward faster diagnosis, better treatments, and real progress in #WomensHealth.

🔗 Study pre-print: www.medrxiv.org/content/10.1...

Identification and Validation of Novel Combinatorial Genetic Risk Factors for Endometriosis across Multiple UK and US Patient Cohorts Background Endometriosis affects about 10% of women usually of reproductive age. It often has severe negative impacts on patients’ quality of life, but the average time to a definitive diagnosis remai...

Our latest study, now in pre-print, has identified & validated 75 new genes linked to #endometriosis.

Actionable insights that will help shorten the 7–10 year diagnostic delay and lead to more effective, personalized treatments.

🔗 www.medrxiv.org/content/10.1...

#WomensHealth #PrecisionMedicine

To find out about Mechanostics, visit precisionlife.com/mechanostics

This week we took part in the launch of Victoria House - London's new home for science and innovation.

Our team showcased Mechanostics® - accelerating diagnosis, improving outcomes, reducing costs, and moving chronic disease care from treatment to prevention.

#PrecisionMedicine #PrecisionLife

▶️ Watch in full here: precisionlife.com/precision-di....

Thank you to the community for your ongoing strength – your voices and experiences are driving science forward.

#SevereMEDay #MECFS #LongCOVID #PrecisionMedicine #Genomics #ClinicalTrials #DrugRepurposing #MyalgicE

🎥 As part of today’s recognition of #SevereME, we’re sharing this recent presentation by our Co-founder, Rowan Gardner (@rowanbio.bsky.social‬), given at International ME Conference: 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗧𝗲𝘀𝘁𝘀 𝗮𝗻𝗱 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗠𝗘.

We are now running 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗨𝗦 to validate new non-invasive diagnostic and therapeutic options – a major step toward faster diagnosis, targeted care, and hope for millions of patients.

Thanks to you, we’ve:
✔️ Confirmed the 𝗳𝗶𝗿𝘀𝘁-𝗲𝘃𝗲𝗿 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 for ME/CFS and long COVID
✔️ Identified 𝘀𝗵𝗮𝗿𝗲𝗱 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀 between both conditions
✔️ Discovered genes that 𝗿𝗲𝘀𝗶𝘀𝘁 𝗮𝗻𝗱 𝗽𝗿𝗼𝘁𝗲𝗰𝘁 against ME

We are deeply grateful to the ME community whose participation in research has enabled ground-breaking progress in understanding this long-neglected condition so that new diagnostic tools and drug treatment can be developed with greater clarity.

𝗧𝗼𝗱𝗮𝘆 𝗶𝘀 𝗦𝗲𝘃𝗲𝗿𝗲 𝗠𝗘 𝗗𝗮𝘆 – a moment to acknowledge the strength, resilience, and determination of those living with the most debilitating forms of Myalgic Encephalomyelitis.

Millions are still waiting for answers. Ahead of #SevereMEAwarenessDay, we’re reaffirming our support and using genetic insights to develop the first non-invasive mechanostic tests to accelerate diagnosis and improve care.

🔗 precisionlife.com/blog-support...

#MECFS #LongCOVID

We fully support our partners at @actionforme.bsky.social in their response to the UK government's ME/CFS Delivery Plan as a positive and necessary step forward – but that much more is needed to deliver real change, faster, for people with ME. #pwME #MECFS #MyalgicE #MyalgicEncephalomyelitis

PrecisionLife | Blog | Mechanism-Based Precision Medicine Learn how mechanostics and mechanism-based precision medicine can transform the future of the UK NHS and healthcare globally - read the article.

Thanks Oevie. We’ve shown how this approach works in over 60 complex, chronic diseases including long COVID, ME/CFS, endometriosis, autoimmune conditions, ALS and type-II diabetes complications – with multiple clinical studies running. Further details in the article: precisionlife.com/future-now